NiKang Therapeutics announced the completion of an oversubscribed $200 million series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors.…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.